May. 20 at 4:51 PM
Jupiter Neurosciences, Inc. (Nasdaq:
$JUNS ) announced the company has entered into a term sheet to acquire exclusive, perpetual U.S. licensing rights to ALA-002, the lead drug candidate of PharmAla Biotech Holdings Inc. (CSE:
$MDMA.CSE ; OTCQB:
$MDXXF ). Under the term sheet, which the company describes as including up to
$100 million in total potential consideration, Jupiter would make an upfront payment of
$3.33 million, consisting of
$1.5 million in cash and
$1.83 million in JUNS common stock, with additional development milestone payments and single-digit royalties as the product is developed, approved, and commercialized.
Jupiter Neurosciences is a B2i Digital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
ALA-002 is a patented, non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity (
$NCE). It is engineered to potentially improve cardiovascular safety and reduce abuse liability versus racemic MDMA, while preserving the pro-social and therapeutic properties central to MDMA-assisted therapy.
Transaction and pipeline highlights:
• Exclusive, perpetual U.S. rights to a next-generation MDMA NCE that expands Jupiter's CNS-focused therapeutic pipeline
• PharmAla's MDMA supply is in active U.S. government-sponsored VA and DHA clinical trials
• Positioned within an emerging regulated U.S. psychedelic therapeutics market that analysts project could reach approximately
$6 billion to
$15 billion annually in the early-to-mid 2030s
• Timing follows the April 18, 2026 federal Executive Order directing the FDA and DEA to expand access to investigational psychedelic therapies
Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences, commented, "This proposed transaction is strategically aligned with Jupiter's long-term focus on CNS innovation and the development of therapies intended to address longevity, brain health, neuroplasticity, and serious neuropsychiatric conditions."
D. Boral Capital, LLC is acting as sole financial advisor to Jupiter Neurosciences. The proposed transaction remains subject to due diligence, negotiation and execution of definitive agreements, and customary closing conditions.
See the press release: https://www.globenewswire.com/news-release/2026/05/20/3298378/0/en/jupiter-neurosciences-secures-100m-term-sheet-for-exclusive-u-s-rights-to-ala-002-a-next-generation-mdma-therapeutic-from-pharmala-biotech.html
Jupiter Neurosciences, Inc. (Nasdaq:
$JUNS ) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
